FDA Cosmetic Regulations FAQ: MoCRA Updates for 2026

FDA cosmetic regulations are the federal rules governing the safety, labeling, and sale of cosmetic products in the United States. Under the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), the FDA has authority over cosmetics sold in interstate commerce. These regulations cover facility registration, product listing, safety substantiation, labeling requirements, and adverse event reporting.

MoCRA (Modernization of Cosmetics Regulation Act) is landmark legislation signed into law on December 29, 2022. It represents the most significant expansion of FDA cosmetic authority since 1938. Key changes include: mandatory facility registration (previously voluntary), required product listing, mandatory serious adverse event reporting, safety substantiation requirements, new labeling rules for fragrance allergens, and FDA authority to issue mandatory recalls.

Anyone who manufactures, processes, packs, or holds cosmetics for distribution in the United States must comply with FDA cosmetic regulations. This includes US-based companies and foreign companies exporting to the US market. Specifically, facility registration applies to manufacturing and processing facilities, product listing applies to anyone marketing cosmetics in the US, and adverse event reporting applies to responsible persons for each product.

Under MoCRA, facilities that manufacture or process cosmetics for US distribution must register with the FDA through the Cosmetics Direct portal. Registration requires providing facility name and address, contact information, product categories manufactured, and US Agent details for foreign facilities. Initial registration deadline was December 29, 2023, with biennial (every 2 years) renewal required. Updates must be submitted within 60 days of any material changes.

Every cosmetic product distributed in the US must be listed with the FDA. Product listing requires the product name, product category, ingredient list (in descending order of predominance), responsible person information, and label image. Products on the market before December 29, 2023 should have been listed by July 1, 2024. New products must be listed within 120 days of market entry.

MoCRA introduced new labeling requirements in addition to existing FDA labeling regulations in 21 CFR Part 701. Key requirements include: contact information for reporting adverse events, standard ingredient labeling rules (INCI names, descending order), and required warning statements for certain product types. Labels must not be false or misleading. Note: Fragrance allergen labeling requirements are PENDING — FDA missed its December 2025 statutory deadline and proposed rule is expected May 2026.

Safety substantiation means having adequate evidence to support that a cosmetic product is safe for its intended use. Under MoCRA, responsible persons must ensure adequate substantiation of safety exists for each product. This typically includes toxicological data on ingredients, stability testing, microbiological testing where appropriate, and documentation available for FDA review. Unlike the EU's CPSR, there is no required format, but records must be maintained and accessible.

MoCRA requires mandatory reporting of serious adverse events to the FDA. A serious adverse event is one that results in death, a life-threatening experience, inpatient hospitalization, persistent or significant disability or incapacity, congenital anomaly or birth defect, or requires medical or surgical intervention to prevent one of these outcomes. Reports must be submitted within 15 business days of receiving the information. Non-serious adverse events are not required to be reported but should be documented.

Yes. Businesses with less than $1 million in average annual gross cosmetic sales (over 3 years) are exempt from facility registration, product listing, and GMP requirements. However, there is NO exemption from adverse event reporting — all serious events must be reported within 15 business days. Small businesses receive reduced record retention (3 years vs. 6 years). CRITICAL: Exemptions do NOT apply if you manufacture ANY high-risk products: eye-contact cosmetics (mascara, eyeliner), injectable products, internal-use products, or long-lasting appearance-altering products.

No. As of January 2026, FDA has not finalized Good Manufacturing Practice (GMP) regulations for cosmetics. The original December 2024 deadline was missed, and the FDA's Unified Agenda shows GMP in 'long-term actions' with uncertain timing. Companies should follow ISO 22716 or equivalent industry standards while awaiting formal regulations.

FDA has various enforcement tools for MoCRA non-compliance: Warning letters issued to facilities out of compliance, import alerts that can block products from foreign unregistered facilities, mandatory recall authority for contaminated or unsafe products, inspection authority with records access requirements, and potential seizure of violative products. While criminal penalties exist for serious violations, FDA typically starts with warning letters and corrective action requests.

FDA may inspect cosmetic facilities as part of their compliance program. During inspections, FDA investigators may review facility registration and product listing records, manufacturing and quality control records, adverse event records, safety substantiation documentation, and labeling and labeling compliance. Facilities should be prepared for unannounced inspections. Under MoCRA, FDA has explicit records access authority during inspections.

Official FDA cosmetic guidance is available at FDA.gov/cosmetics. Key resources include the FDA Cosmetics main portal for general information, FDA's MoCRA Overview page for law-specific guidance, Cosmetics Direct portal (direct.fda.gov) for registration and listing, FDA Guidance Documents for detailed compliance guidance, and 21 CFR Parts 700-740 for cosmetic regulations in the Code of Federal Regulations.

No, cosmetics (unlike drugs) do not require pre-market FDA approval. However, cosmetics must comply with all applicable regulations including not being adulterated (containing harmful substances) or misbranded (having false or misleading labeling). Under MoCRA, you must also register your facility, list your products, and ensure safety substantiation exists. The responsible person is accountable for compliance.

Under FDA regulations, the classification depends on intended use. Cosmetics are products intended to cleanse, beautify, promote attractiveness, or alter appearance without affecting the body's structure or function. Drugs are products intended to diagnose, cure, mitigate, treat, or prevent disease, or to affect the structure or function of the body. Products making drug claims (like 'anti-aging' or 'treats acne') may be regulated as drugs or cosmetic-drugs. Classification matters because drugs have much stricter requirements including pre-market approval.

MoCRA has significant implications for imported cosmetics. Foreign manufacturing facilities must register with the FDA, products must be listed before or shortly after importation, a US Agent must be designated for foreign facilities, products from unregistered facilities may face import alerts, and FDA can inspect foreign facilities. Importers should verify their foreign suppliers are MoCRA compliant to avoid customs holds and import refusals.